Once-daily injectable liraglutide represents one of the first GLP-1 receptor agonists marketed for use in 2010, but further progress in the class has led to the development of once-weekly injectable and once-daily orally administered medications [10]
Figure 1 Table 1 Effects of GIP receptor agonism or antagonism on glycemic control, body weight, and energy balance in animal models of obesity and diabetes (modified according to Campbell and Nauck) (47, 49)
Combining these treatments can be highly effective for managing the multi-faceted symptoms of PCOS
Immunohistochemical evidence for apoptosis in Alzheimers disease
Mental health: Obesity is often associated with low self-esteem, depression, and anxiety due to societal stigma and body image concerns
Meanwhile, Stadlers lab is applying spatial proteomics to identify optimal treatments for cohorts of patients with urothelial carcinoma